Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. More Details
+ 2 more risks
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Synthetic Biologics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: SYN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: SYN exceeded the US Biotechs industry which returned 22.3% over the past year.
Return vs Market: SYN underperformed the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Synthetic Biologics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDavid Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)
2 months ago | Simply Wall StWho Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?
11 months ago | Simply Wall StCould Synthetic Biologics, Inc.'s (NYSEMKT:SYN) Investor Composition Influence The Stock Price?
Is Synthetic Biologics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Synthetic Biologics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Synthetic Biologics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Synthetic Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SYN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if SYN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYN's Return on Equity is forecast to be high in 3 years time
How has Synthetic Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYN is currently unprofitable.
Growing Profit Margin: SYN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SYN is unprofitable, but has reduced losses over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare SYN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: SYN has a negative Return on Equity (-192.39%), as it is currently unprofitable.
How is Synthetic Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: SYN's short term assets ($7.9M) exceed its short term liabilities ($3.0M).
Long Term Liabilities: SYN's short term assets ($7.9M) exceed its long term liabilities ($186.0K).
Debt to Equity History and Analysis
Debt Level: SYN is debt free.
Reducing Debt: SYN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SYN has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.7% each year.
What is Synthetic Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Steve Shallcross (59 yo)
Mr. Steven A. Shallcross, also known as Steve, CPA, is Director at Twin Vee Powercats Co. since April 8, 2021. He has been Independent Director of Elys Game Technology, Corp. (formerly known as Newgioco Gr...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.06M) is above average for companies of similar size in the US market ($USD543.98K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Board: SYN's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SYN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 671.5%.
Synthetic Biologics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Synthetic Biologics, Inc.
- Ticker: SYN
- Exchange: AMEX
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$8.066m
- Shares outstanding: 129.65m
- Website: https://www.syntheticbiologics.com
Number of Employees
- Synthetic Biologics, Inc.
- 9605 Medical Center Drive
- Suite 270
- United States
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 23:44|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.